Emerging treatments for viral retinitis

Mostafa A. Nokta, Stephen G. Hausrath, Richard B Pollard

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cytomegalovirus is the most frequent cause of viral retinitis. It rarely causes disease in immunocompetent individuals, but is an important cause of retinitis in immunocompromised patients. Therapy with ganciclovir or foscarnet may result in a decrease in the morbidity related to cytomegalovirus, but problems with drug toxicity and development of clinical and viral resistance mandate additional therapeutic approaches. Preliminary phase I/II clinical trials suggest that human neutralising monoclonal antibodies to cytomegalovirus plus ganciclovir or foscarnet may be more effective than either ganciclovir or foscarnet alone for treating cytomegalovirus retinitis and in prolonging the time to cytomegalovirus disease progression in patients with AIDS. An approach based on an antisense oligonucleotide complementary to cytomegalovirus messenger RNA also shows promise.

Original languageEnglish (US)
Pages (from-to)423-432
Number of pages10
JournalBioDrugs
Volume7
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

Retinitis
Cytomegalovirus
Foscarnet
Ganciclovir
Cytomegalovirus Retinitis
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Antisense Oligonucleotides
Immunocompromised Host
Neutralizing Antibodies
Drug-Related Side Effects and Adverse Reactions
Disease Progression
Acquired Immunodeficiency Syndrome
Monoclonal Antibodies
Morbidity
Messenger RNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nokta, M. A., Hausrath, S. G., & Pollard, R. B. (1997). Emerging treatments for viral retinitis. BioDrugs, 7(6), 423-432.

Emerging treatments for viral retinitis. / Nokta, Mostafa A.; Hausrath, Stephen G.; Pollard, Richard B.

In: BioDrugs, Vol. 7, No. 6, 1997, p. 423-432.

Research output: Contribution to journalArticle

Nokta, MA, Hausrath, SG & Pollard, RB 1997, 'Emerging treatments for viral retinitis', BioDrugs, vol. 7, no. 6, pp. 423-432.
Nokta MA, Hausrath SG, Pollard RB. Emerging treatments for viral retinitis. BioDrugs. 1997;7(6):423-432.
Nokta, Mostafa A. ; Hausrath, Stephen G. ; Pollard, Richard B. / Emerging treatments for viral retinitis. In: BioDrugs. 1997 ; Vol. 7, No. 6. pp. 423-432.
@article{c213f56084954d8b8a9a4aadaa6d0e9c,
title = "Emerging treatments for viral retinitis",
abstract = "Cytomegalovirus is the most frequent cause of viral retinitis. It rarely causes disease in immunocompetent individuals, but is an important cause of retinitis in immunocompromised patients. Therapy with ganciclovir or foscarnet may result in a decrease in the morbidity related to cytomegalovirus, but problems with drug toxicity and development of clinical and viral resistance mandate additional therapeutic approaches. Preliminary phase I/II clinical trials suggest that human neutralising monoclonal antibodies to cytomegalovirus plus ganciclovir or foscarnet may be more effective than either ganciclovir or foscarnet alone for treating cytomegalovirus retinitis and in prolonging the time to cytomegalovirus disease progression in patients with AIDS. An approach based on an antisense oligonucleotide complementary to cytomegalovirus messenger RNA also shows promise.",
author = "Nokta, {Mostafa A.} and Hausrath, {Stephen G.} and Pollard, {Richard B}",
year = "1997",
language = "English (US)",
volume = "7",
pages = "423--432",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Emerging treatments for viral retinitis

AU - Nokta, Mostafa A.

AU - Hausrath, Stephen G.

AU - Pollard, Richard B

PY - 1997

Y1 - 1997

N2 - Cytomegalovirus is the most frequent cause of viral retinitis. It rarely causes disease in immunocompetent individuals, but is an important cause of retinitis in immunocompromised patients. Therapy with ganciclovir or foscarnet may result in a decrease in the morbidity related to cytomegalovirus, but problems with drug toxicity and development of clinical and viral resistance mandate additional therapeutic approaches. Preliminary phase I/II clinical trials suggest that human neutralising monoclonal antibodies to cytomegalovirus plus ganciclovir or foscarnet may be more effective than either ganciclovir or foscarnet alone for treating cytomegalovirus retinitis and in prolonging the time to cytomegalovirus disease progression in patients with AIDS. An approach based on an antisense oligonucleotide complementary to cytomegalovirus messenger RNA also shows promise.

AB - Cytomegalovirus is the most frequent cause of viral retinitis. It rarely causes disease in immunocompetent individuals, but is an important cause of retinitis in immunocompromised patients. Therapy with ganciclovir or foscarnet may result in a decrease in the morbidity related to cytomegalovirus, but problems with drug toxicity and development of clinical and viral resistance mandate additional therapeutic approaches. Preliminary phase I/II clinical trials suggest that human neutralising monoclonal antibodies to cytomegalovirus plus ganciclovir or foscarnet may be more effective than either ganciclovir or foscarnet alone for treating cytomegalovirus retinitis and in prolonging the time to cytomegalovirus disease progression in patients with AIDS. An approach based on an antisense oligonucleotide complementary to cytomegalovirus messenger RNA also shows promise.

UR - http://www.scopus.com/inward/record.url?scp=0030756055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030756055&partnerID=8YFLogxK

M3 - Article

C2 - 18020490

AN - SCOPUS:0030756055

VL - 7

SP - 423

EP - 432

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 6

ER -